192 related articles for article (PubMed ID: 11771732)
41. Herpes simplex virus resistance to acyclovir: clinical relevance.
Pottage JC; Kessler HA
Infect Agents Dis; 1995 Sep; 4(3):115-24. PubMed ID: 8548189
[TBL] [Abstract][Full Text] [Related]
42. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient.
Kost RG; Hill EL; Tigges M; Straus SE
N Engl J Med; 1993 Dec; 329(24):1777-82. PubMed ID: 8232486
[No Abstract] [Full Text] [Related]
43. Screening for acyclovir-resistant herpes simplex virus isolates from clinical samples.
Mah IW; Kuo BI; Wei HY; Tsai CH; Liu WT
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1997 Feb; 30(1):51-4. PubMed ID: 10592810
[TBL] [Abstract][Full Text] [Related]
44. Suppression of recurrent genital herpes simplex virus type 2 infection by Rhus javanica in guinea pigs.
Nakano M; Kurokawa M; Hozumi T; Saito A; Ida M; Morohashi M; Namba T; Kawana T; Shiraki K
Antiviral Res; 1998 Jul; 39(1):25-33. PubMed ID: 9754947
[TBL] [Abstract][Full Text] [Related]
45. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Rose WA; Tuthill C; Pyles RB
Int J Antimicrob Agents; 2008 Sep; 32(3):262-6. PubMed ID: 18619817
[TBL] [Abstract][Full Text] [Related]
46. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro.
Schuhmacher A; Reichling J; Schnitzler P
Phytomedicine; 2003; 10(6-7):504-10. PubMed ID: 13678235
[TBL] [Abstract][Full Text] [Related]
47. The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women.
Strachan E; Saracino M; Selke S; Magaret A; Buchwald D; Wald A
Brain Behav Immun; 2011 Oct; 25(7):1475-81. PubMed ID: 21693182
[TBL] [Abstract][Full Text] [Related]
48. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial.
Scott LL; Hollier LM; McIntire D; Sanchez PJ; Jackson GL; Wendel GD
Infect Dis Obstet Gynecol; 2001; 9(2):75-80. PubMed ID: 11495557
[TBL] [Abstract][Full Text] [Related]
49. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
Handsfield HH; Warren T; Werner M; Phillips JA
Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
[TBL] [Abstract][Full Text] [Related]
50. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
[TBL] [Abstract][Full Text] [Related]
51. Long-term suppressive therapy with acyclovir for recurrent genital herpes.
Baker DA
J Int Med Res; 1994; 22 Suppl 1():24A-31A; discussion 31A-32A. PubMed ID: 8063021
[TBL] [Abstract][Full Text] [Related]
52. Anti HSV-2 activity of Peganum harmala (L.) and isolation of the active compound.
Benzekri R; Bouslama L; Papetti A; Hammami M; Smaoui A; Limam F
Microb Pathog; 2018 Jan; 114():291-298. PubMed ID: 29223449
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):501-13. PubMed ID: 10772730
[TBL] [Abstract][Full Text] [Related]
54. Suppression of infectious virus spread to the liver by foscarnet following lethal infection of acyclovir-resistant herpes simplex virus type 2 in mice.
Li YY; Minagawa H; Tanaka S; Mori R
Antiviral Res; 1995 May; 27(1-2):111-21. PubMed ID: 7486949
[TBL] [Abstract][Full Text] [Related]
55. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists, number 57, November 2004. Gynecologic herpes simplex virus infections.
ACOG Committee on Practice Bulletins--Gynecology
Obstet Gynecol; 2004 Nov; 104(5 Pt 1):1111-8. PubMed ID: 15516420
[TBL] [Abstract][Full Text] [Related]
56. Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
Arinze F; Shaver A; Raffanti S
Infection; 2017 Oct; 45(5):705-707. PubMed ID: 28508238
[TBL] [Abstract][Full Text] [Related]
57. In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients.
McLaren C; Corey L; Dekket C; Barry DW
J Infect Dis; 1983 Nov; 148(5):868-75. PubMed ID: 6313820
[TBL] [Abstract][Full Text] [Related]
58. Detection of a novel mutation conferring acyclovir resistance and consecutive treatment failure in an HIV-positive patient with recurrent HSV-2 infection.
Schleenvoigt BT; Pletz MW; Deinhardt-Emmer S; Sauerbrei A
J Glob Antimicrob Resist; 2018 Mar; 12():20. PubMed ID: 29179992
[No Abstract] [Full Text] [Related]
59. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Safrin S; Crumpacker C; Chatis P; Davis R; Hafner R; Rush J; Kessler HA; Landry B; Mills J
N Engl J Med; 1991 Aug; 325(8):551-5. PubMed ID: 1649971
[TBL] [Abstract][Full Text] [Related]
60. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.
Sarisky RT; Bacon TH; Boon RJ; Duffy KE; Esser KM; Leary J; Locke LA; Nguyen TT; Quail MR; Saltzman R
Arch Virol; 2003 Sep; 148(9):1757-69. PubMed ID: 14505088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
